Journal
EPIGENETICS
Volume 7, Issue 4, Pages 409-414Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/epi.19551
Keywords
DNA methylation; prenatal exposures; antidepressants; depressive symptoms; HumanMethylation27 BeadChip; Infinium
Funding
- Specialized Center for Research [P50 MH 68036]
- Translational Research Center in Behavioral Sciences (TRCBS) [P50 MH077928]
- Emory Biomarker Service Center
- NIH
- AFSP
- Schering Plough Pharmaceuticals
- NARSAD
- Wyeth
- BMS
- Cyberonics
- Eli Lilly
- Forest
- Janssen
- Novartis
- GSK
- Pfizer
- [RC1 MH088609]
- [MH085806]
Ask authors/readers for more resources
Prenatal exposure both to maternal psychiatric illness and psychiatric medication has been linked with adverse child outcomes that affect physiological, emotional and psychiatric development. Studies suggest that epigenetic mechanisms, such as DNA methylation, may facilitate these effects. In this report, we explore the association between maternal psychiatric illness and treatment during pregnancy and neonatal DNA methylation patterns in a prospectively-characterized clinical cohort of 201 dyads. Associations between the percent of umbilical cord blood DNA methylated at 27,578 CpG sites and maternal psychiatric diagnosis, symptoms and antidepressant use were evaluated by fitting a separate linear mixed effects model for each CpG site. There were no significant changes in neonatal DNA methylation attributable to maternal psychiatric diagnosis or depressive symptoms during pregnancy. Exposure to an antidepressant medication was associated with differential methylation of CpG sites in TNFRSF21 and CHRNA2 (false discovery rate < 0.05), but the average difference in methylation for both CpG sites was less than 3% between each group. The results were not specific to type of antidepressant or duration of the exposure. This study suggests that there are no large effects of maternal psychiatric illness, depressive symptoms or prenatal exposure to antidepressants on neonatal DNA methylation. Delineation of the influence of maternal psychiatric illness and pharmacological exposures on the developing fetuses has critical implications for clinical care during pregnancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available